证券代码：300765 证券简称：新诺威 公告编号：2023-058 石药集团新诺威制药股份有限公司 关于筹划对石药集团巨石生物制药有限公司增资暨 关联交易的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、石药集团新诺威制药股份有限公司（以下简称"公司"、"上市公司"） 正在筹划对石药集团巨石生物制药有限公司（以下简称"巨石生物"或"标的公 司"）实施现金增资（以下简称"本次增资"），取得标的公司 51%以上的股权， 实现对标的公司的控股。相关各方已于 2023 年 8 月 30 日签署了《关于石药集团 巨石生物制药有限公司增资之意向协议》（以下简称"《增资意向协议》"）。 2、本次增资构成关联交易。经初步研究和测算，本次交易预计不构成重大 资产重组。 3、本次签署的《增资意向协议》仅为各方合作意愿的意向性约定，具体的 交易方案及相关交易条款以各方最终签署的正式协议为准。 4、本次增资尚处于筹划阶段，具体交易方案仍处于论证协商中，并需按照 相关法律、法规及公司章程的规定履行必要的决策和审批程序，存在未能通过该 等决策、审批程序的风险 ...

（1）首次公开发行募集资金情况 石药集团新诺威制药股份有限公司经中国证券监督管理委员会《关于核准石 药集团新诺威制药股份有限公司首次公开发行股票的批复》（证监许可[2019]288 号）核准，并经深圳证券交易所《关于石药集团新诺威制药股份有限公司人民币 普通股股票在创业板上市的通知》（深证上[2019]133 号）同意，公司公开发行的 人民币普通股股票已于 2019 年 3 月 22 日在深圳证券交易所创业板上市交易。公 司首次公开发行人民币普通股（A 股）50,000,000 股，发行价格 24.47 元/股，募 集资金总额 1,223,500,000.00 元，保荐机构（主承销商）安信证券有限公司扣除 承销及保荐费用 71,271,300.00 元后，于 2019 年 3 月 19 日将 1,152,228,700.00 元 划至公司募集资金专户。再行扣除审计验资费用、律师费用、信息披露费用及发 行手续费合计 9,819,490.53 元后，募集资金净额为 1,142,409,209.47 元。 石药集团新诺威制药股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 根据《深圳证券交易所上市公 ...

证券代码：300765 证券简称：新诺威 公告编号：2023-057 石药集团新诺威制药股份有限公司 关于 2023 年半年度募集资金存放与使用情况的专项报告 及 2023 年半年度报告的更正公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1 | 募集资金 | 序号 | 开户银行 | 开户公司 | 银行账户 | 账户余额 | 存放方式 | | --- | --- | --- | --- | --- | --- | --- | | | 6 | 上海浦东发展银 行股份有限公司 石家庄分行 | 石药圣雪 | 450100788011000 03503 | 7,882,301 | 活期存储 | | | | 合计 | | | 308,649,526.01 | | | | | 总计 | | | 693,381,790.66 | - | 更正后： | 募集资金 | 序号 | 开户银行 | 开户公司 | 银行账户 | 账户余额 | 存放方式 | | --- | --- | --- | --- | --- | --- | --- | | 首次公开发 行募集资金 | 1 | ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥1.31 billion, representing a 5.47% increase compared to ¥1.04 billion in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2023 was approximately ¥400.62 million, a 20.72% increase from ¥302.37 million in the previous year[21]. - The net profit after deducting non-recurring gains and losses was approximately ¥394.04 million, reflecting a 30.59% increase compared to ¥301.73 million in the same period last year[21]. - The net cash flow from operating activities was approximately ¥346.37 million, up 32.99% from ¥211.31 million in the previous year[21]. - Total assets at the end of the reporting period were approximately ¥5.28 billion, a 15.11% increase from ¥4.58 billion at the end of the previous year[21]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥4.73 billion, representing a 20.15% increase from ¥3.94 billion at the end of the previous year[21]. - The basic earnings per share for the first half of 2023 were ¥0.3507, a 3.85% increase from ¥0.3377 in the previous year[21]. - The diluted earnings per share were also ¥0.3507, reflecting the same increase of 3.85% compared to the previous year[21]. - The weighted average return on equity was 9.21%, a slight decrease of 0.39% from 9.60% in the previous year[21]. - The company reported a gross margin of 45%, reflecting improved operational efficiency compared to the previous year[40]. Market Expansion and Product Development - The company is focusing on high-end market development, increasing the sales proportion of high-end products[34]. - The company is actively exploring new retail channels and e-commerce platforms to diversify its sales strategy[35]. - The company has launched over 20 new functional health products, achieving a production capacity of 130 million units during the reporting period[36]. - The company is focusing on expanding its product line in areas such as eye care, liver protection, and sports nutrition through continuous market research and innovation[36]. - The company is actively pursuing market expansion and innovation in functional products to meet consumer and industry demands[36]. - The company is collaborating with various subsidiaries to optimize the production and approval process of health food products[39]. - The company plans to enhance its supply chain logistics, aiming to reduce delivery times by 15% in the next quarter[40]. - The company is investing in R&D for new health supplements, with a budget allocation of 200 million CNY for the next fiscal year[40]. - The company is exploring potential acquisitions to enhance its product portfolio, targeting companies with complementary health products[40]. - The company has established overseas sales offices to enhance market penetration in North America, South America, Europe, and South Asia[34]. Sustainability and Compliance - The company has achieved a silver rating in the Ecovadis assessment, reflecting its commitment to sustainable practices[34]. - The company is committed to adhering to the disclosure requirements set by the Shenzhen Stock Exchange for food and beverage manufacturing[36]. - The company emphasizes strict budget management and cost control in the implementation of fundraising projects to enhance efficiency[78]. - The company has established a comprehensive food safety quality control system and has never experienced a major food safety incident since its establishment[87]. - The company strictly adheres to various environmental protection laws and regulations, including the Environmental Protection Law of the People's Republic of China[96]. - The company has implemented a comprehensive energy management system to reduce carbon emissions and improve energy efficiency, aligning with national energy-saving regulations[106]. Shareholder and Capital Management - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[4]. - The total number of shares increased to 1,170,742,154 after a capital reserve conversion, with a distribution of 8 shares for every 10 held during the 2022 profit distribution[133]. - The company issued 31,486,146 new ordinary shares at a price of ¥15.88 per share, raising a total of ¥499,999,998.48, with a net amount of ¥488,195,415.53 after deducting fees[72]. - The largest shareholder, Shijiazhuang Pharmaceutical Group, holds 73.35% of the shares, amounting to 381,649,082 shares[142]. - The company has not reported any major contracts or guarantees during the reporting period[128][127]. Operational Efficiency and Cost Management - The company reported a decrease in direct material costs by 10.57% year-on-year, with direct material costs amounting to CNY 351.85 million, which constituted 50.99% of the total operating costs[55]. - The sales expenses decreased by 11.34% to CNY 108,238,686.40, down from CNY 122,079,824.10 in the previous year, indicating improved cost management[62]. - The company's management expenses increased by 44.95% to CNY 39,630,755.86, primarily due to higher personnel costs and depreciation[62]. - The company has implemented measures to refine responsibilities and improve operational procedures, contributing to overall efficiency and effectiveness[36]. Risks and Challenges - The company faces market competition risks due to high quality and brand requirements from downstream customers in the functional raw materials industry[85]. - The company is exposed to raw material price fluctuation risks, with a high proportion of direct materials in operating costs[86]. - The company emphasizes continuous R&D investment and market demand orientation to mitigate new product development risks[87]. - The company will closely monitor exchange rate fluctuations as its export business is a significant source of revenue and profit[86].

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥1.31 billion, representing a 5.47% increase compared to the same period last year[21]. - The net profit attributable to shareholders for the first half of 2023 was approximately ¥400.62 million, reflecting a 20.72% increase year-on-year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥394.04 million, which is a 30.59% increase compared to the previous year[21]. - The net cash flow from operating activities for the first half of 2023 was approximately ¥346.37 million, up 32.99% from the same period last year[21]. - Total assets as of June 30, 2023, were approximately ¥5.28 billion, marking a 15.11% increase from the end of the previous year[21]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥4.73 billion, which is a 20.15% increase year-on-year[21]. - The basic earnings per share for the first half of 2023 were ¥0.3507, a 3.85% increase compared to the same period last year[21]. - The company reported a total comprehensive income of CNY 402.49 million for the first half of 2023, compared to CNY 332.50 million in the same period of 2022, marking an increase of 20.9%[167]. - The company reported a significant increase in user data, with a total of 1.5 million active users, reflecting a growth rate of 30% compared to the previous year[178]. Market Expansion and Product Development - The company is focusing on high-end market development, increasing the sales proportion of high-end products[34]. - The company is actively exploring new retail channels and e-commerce platforms to diversify its sales strategy[35]. - The company has launched over 20 new functional health products, achieving a production capacity of 130 million units during the reporting period[36]. - The company has obtained 18 new health food product approvals during the reporting period, expanding its product line and enhancing market competitiveness[35]. - The company is expanding its market presence in Southeast Asia, targeting a 20% market share in the region by 2025[175]. - New product launches are expected to contribute an additional 200 million CNY in revenue by the end of 2023[176]. - The company has initiated two strategic acquisitions in the healthcare sector, expected to enhance its product portfolio and increase revenue by 10% in the next fiscal year[179]. - The company plans to continue expanding its market presence and invest in new product development to drive future growth[183]. Research and Development - The company is investing in research and development for new health supplements, with a budget increase of 30% for R&D activities in 2023[40]. - Research and development expenses increased to CNY 22,313,725.52, a rise of 61.5% compared to CNY 13,813,998.98 in the previous year[163]. - The company plans to increase its R&D investment by 15% in the next fiscal year to enhance product development and innovation capabilities[175]. - The company has implemented new equipment and processes to improve production efficiency and product quality[34]. Financial Management and Investments - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[4]. - The total amount of funds raised during the reporting period was ¥163,060.46 million, with ¥20,421.5 million invested from the raised funds[70]. - The company's financial expenses decreased by 32.82% to -¥41,017,226.49, mainly due to an increase in interest income[60]. - The total cash inflow from financing activities was CNY 488,799,998.48, with cash outflows for dividend payments amounting to CNY 97,561,846.20[172]. Risk Management - The company has outlined potential risk factors and countermeasures in its management discussion and analysis section[3]. - The company faces market competition risks, particularly in the functional raw materials industry, which may lead to increased competition and potential declines in gross margins[83]. - The company has implemented measures to optimize supply chain management and reduce costs to mitigate risks associated with raw material price fluctuations[84]. - The company is exposed to exchange rate risks due to its reliance on export business, which is a significant source of revenue and profit[84]. Environmental and Social Responsibility - The company has established a comprehensive food safety quality control system and has not experienced any major food safety incidents since its inception[85]. - The company emphasizes continuous R&D investment and market demand orientation to mitigate risks associated with new product development[85]. - The company strictly adheres to various environmental protection laws and regulations, including the Environmental Protection Law of the People's Republic of China and the Air Pollution Prevention and Control Law[94]. - The company actively engages in social responsibility, ensuring transparent communication with investors and adhering to a stable dividend policy[105]. Corporate Governance - The company experienced changes in its board of directors, with several members completing their terms on April 7, 2023[89]. - The company appointed a new board secretary and CFO, Dai Long, on April 7, 2023[90]. - The first extraordinary general meeting of 2023 had an investor participation rate of 80.41%[88]. - The company did not implement any stock incentive plans, employee stock ownership plans, or other employee incentive measures during the reporting period[92].

证券代码：300765 证券简称：新诺威 公告编号：2023-051 石药集团新诺威制药股份有限公司 第六届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1、审议并通过《关于公司<2023 年半年度报告>及其摘要的议案》 经审议，监事会认为：《2023 年半年度报告》及《2023 年半年度报告摘要》 的内容符合法律、行政法规、中国证券监督管理委员会和深圳证券交易所的相 关规定，报告内容真实、准确、完整，不存在任何虚假记载、误导性陈述或者 重大遗漏。 具体内容详见公司同日刊载于中国证监会指定创业板信息披露网站巨潮资 讯网（www.cninfo.com.cn）上的相关公告。 一、监事会会议召开情况 石药集团新诺威制药股份有限公司（以下简称"公司"）第六届监事会第三 次会议（以下简称"本次会议"）于 2023 年 8 月 16 日在公司会议室以现场方式 召开，会议通知及补充通知分别于 2023 年 8 月 3 日以专人送达、电话通知等方 式送达全体监事。 会议由公司监事会主席张继勇先生主持。本次会议应出席监事人数 3 人， 实际出席监事人 ...

鉴于石药集团新诺威制药股份有限公司（以下简称"公司"）的全资子公司 石药集团中诺药业（泰州）有限公司下属控股子公司石药集团安沃勤医药（泰州） 有限公司（以下简称"安沃勤医药"）目前已无实际经营业务，为提升公司整体 运营效率，降低管理成本和经营风险，整合公司资源，公司拟依法定程序清算并 注销子公司安沃勤医药。 2023 年 8 月 16 日公司召开第六届董事会第三次会议审议通过了《关于清 算注销控股子公司石药集团安沃勤医药（泰州）有限公司的议案》，同意清算注 销控股子公司安沃勤医药，并授权公司管理层按照法定程序办理清算、注销等相 关事宜。 证券代码：300765 证券简称：新诺威 公告编号：2023-056 石药集团新诺威制药股份有限公司 根据深圳证券交易所《股票上市规则》及《公司章程》等相关规定，本次清 算及注销事项在董事会审批权限范围内，无需提交公司股东大会审议。本次清算 及注销事项不涉及关联交易，亦不构成重大资产重组。 关于清算注销控股子公司的公告 一、 石药集团安沃勤医药（泰州）有限公司的基本情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、统一 ...

石药集团新诺威制药股份有限公司独立董事 关于第六届董事会第三次会议相关事项的独立意见及专项说明 我们作为石药集团新诺威制药股份有限公司（以下简称"公司"）独立董事审 议了公司第六届董事会第三次会议相关议案。根据《公司章程》及《独立董事工 作细则》等制度的相关规定，并参照《关于在上市公司建立独立董事制度的指导 意见》《深圳证券交易所创业板股票上市规则》《上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等法律、法规、规范性文件的规定，本着对公司、 全体股东负责的态度，对公司下列事项进行了认真的了解和查验，现就公司第六 届董事会第三次会议的相关事项发表独立意见并对控股股东及其他关联方占用 公司资金、公司对外担保情况的专项说明，相关情况如下： 一、关于公司《2023 年半年度募集资金存放与使用情况的专项报告》的独 立意见 公司本次注销控股子公司石药集团安沃勤医药（泰州）有限公司符合《公司 法》《公司章程》的有关规定。该公司注销后，不会对公司合并财务报表产生实 质性影响，不会对公司整体业务发展和盈利水平产生不利影响。不存在损害公司 及全体股东，特别是中小投资者利益的情形。 因此，我们一致同意公司清算注销控股 ...

| | 石药集团河北中诚医 | 同 受 最 终控 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 药有限公司及其子公 | 制方控制 | 应收账款 | 211.40 | 1,617.31 | | 1,157.57 | 671.14 货款 | 经营性往来 | | | 司 | | | | | | | | | | | 石药集团内蒙古中诺 | 同 受 最 终控 | 应收账款 | 230.40 | 727.20 | | 680.40 | 277.20 货款 | 经营性往来 | | | 药业有限公司 | 制方控制 | | | | | | | | | | 石药银湖制药有限公 | 同 受 最 终控 | 应收账款 | 172.96 | 599.77 | | 586.64 | 186.09 货款 | 经营性往来 | | | 司 | 制方控制 | | | | | | | | | | CSPC DERMAY | 同 受 最 终控 | 应收账款 | 114.00 | 195.77 | | 195.76 | 114.01 货 ...

证券代码：300765 证券简称：新诺威 公告编号：2023-050 石药集团新诺威制药股份有限公司 第六届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 石药集团新诺威制药股份有限公司（以下简称"公司"）第六届董事会第三 次会议（以下简称"本次会议"）于 2023 年 8 月 16 日在公司会议室以现场加通 讯表决相结合的方式召开，会议通知于 2023 年 8 月 3 日以专人送出、电话通知 等方式送达全体董事。 会议由公司董事长潘卫东先生主持，公司监事与高级管理人员列席了本次会 议。本次会议应出席董事人数 9 人，实际出席董事人数 9 人。出席董事资格、人 数以及召集、召开程序等均符合《中华人民共和国公司法》等法律法规和《石药 集团新诺威制药股份有限公司章程》的规定，本次会议合法有效。 二、董事会会议审议情况 经与会董事充分讨论，本次会议审议并通过了如下议案： 1、审议并通过《关于公司<2023 年半年度报告>及其摘要的议案》 经审议，董事会认为：《2023 年半年度报告》及《2023 年半年度报告摘要》 ...